Table 1.
Biologics approved for the management of gastrointestinal inflammatory and oncological conditions
| Condition/disease | Biologic | FDA approved biosimilar |
| Crohn’s disease | Infliximab (anti-TNFα) | Remsima, Inflectra, Renflexis, Flixabi |
| Adalimumab (anti-TNFα) | Amjevita, Cyltezo | |
| Certolizumab (anti-TNFα) | NA | |
| Vedolizumab (anti-α4-integrin) | NA | |
| Natalizumab (anti-α4-integrin) | NA | |
| Ustekinumab (anti-IL-antibody) | NA | |
| Ulcerative colitis | Infliximab (anti-TNFα) | Remsima, Inflectra, Renflexis, Flixabi |
| Adalimumab (anti-TNFα) | Amjevita, Cyltezo | |
| Golimumab (anti-TNFα) | NA | |
| Colorectal cancer | Bevacizumab (anti-VEGF) | Mvasi |
| Ramucirumab (anti-VEGF) | NA | |
| Cetuximab (anti-EGFR) | NA | |
| Pantimumab (anti-EGFR) | NA | |
| Gastric cancer | Trastuzumab (anti-HER2/neu) | Ogivri |
VEGF: Vascular endothelial growth factor; IL: Interleukin; EGFR: Epidermal growth factor receptor; NA: An FDA approved biosimilar is not available.